Gene · 10499
Papers3,077
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
201 to 220 of 3,077
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Comparison of activity, structure, and dynamics of SF-1 and LRH-1 complexed with small molecule modulators. | J Biol Chem | 2023 | 37328104 | PubTator, text mining | PubMed |
| Modulating retinoid-X-receptor alpha (RXRA) expression sensitizes chronic myeloid leukemia cells to imatinib in vitro and reduces disease burden in vivo. | Front Pharmacol | 2023 | 37324449 | PubTator, text mining | PubMed |
| AhR and HIF-1α Signaling Pathways in Benign Meningioma under Hypoxia. | Int J Cell Biol | 2023 | 37305351 | PubTator, text mining | PubMed |
| Intratumoral Restoration of miR-137 Plus Cholesterol Favors Homeostasis of the miR-137/Coactivator p160/AR Axis and Negatively Modulates Tumor Progression in Advanced Prostate Cancer. | Int J Mol Sci | 2023 | 37298588 | PubTator, text mining | PubMed |
| [Verification of the diagnosis of supratentorial ependymomas by real-time PCR]. | Arkh Patol | 2023 | 37272434 | PubTator, text mining | PubMed |
| Investigation of enzalutamide, docetaxel, and cabazitaxel resistance in the castration resistant prostate cancer cell line C4 using genome-wide CRISPR/Cas9 screening. | Sci Rep | 2023 | 37270558 | PubTator, text mining | PubMed |
| Dietary (poly)phenols mitigate inflammatory bowel disease: Therapeutic targets, mechanisms of action, and clinical observations. | Curr Res Food Sci | 2023 | 37266414 | PubTator, text mining | PubMed |
| An Update on Tamoxifen and the Chemo-Preventive Potential of Vitamin E in Breast Cancer Management. | J Pers Med | 2023 | 37240924 | PubTator, text mining | PubMed |
| Prognostic Values of Gene Copy Number Alterations in Prostate Cancer. | Genes (Basel) | 2023 | 37239316 | PubTator, text mining | PubMed |
| Recent advances in understanding DNA methylation of prostate cancer. | Front Oncol | 2023 | 37234978 | PubTator, text mining | PubMed |
| NKX3.1 immunohistochemistry and methylome profiling in mesenchymal chondrosarcoma: additional diagnostic value for a well-defined disease? | Pathology | 2023 | 37225644 | PubTator, text mining | PubMed |
| PD-L1 expression, morphology, and molecular characteristic of a subset of aggressive uterine tumor resembling ovarian sex cord tumor and a literature review. | J Ovarian Res | 2023 | 37221583 | PubTator, text mining | PubMed |
| New insights for infection mechanism and potential targets of COVID-19: Three Chinese patent medicines and three Chinese medicine formulas as promising therapeutic approaches. | Chin Herb Med | 2023 | 37220535 | PubTator, text mining | PubMed |
| Targeted treatment of solid tumors in pediatric precision oncology. | Front Oncol | 2023 | 37213274 | PubTator, text mining | PubMed |
| HEY1-NCOA2 expression modulates chondrogenic differentiation and induces mesenchymal chondrosarcoma in mice. | JCI Insight | 2023 | 37212282 | PubTator, text mining | PubMed |
| Targeting the Src N-terminal regulatory element in cancer. | Oncotarget | 2023 | 37204272 | PubTator, text mining | PubMed |
| Epigenetic differences in NCOA2: a novel biomarker that predicts prognosis in clear cell renal cell carcinoma. | Am J Transl Res | 2023 | 37193192 | PubTator, text mining | PubMed |
| Sirtuins at the Crossroads between Mitochondrial Quality Control and Neurodegenerative Diseases: Structure, Regulation, Modifications, and Modulators. | Aging Dis | 2023 | 37191431 | PubTator, text mining | PubMed |
| Clinical Characteristics, Treatment Considerations, and Outcomes of Infants with Rhabdomyosarcoma. | Cancers (Basel) | 2023 | 37190224 | PubTator, text mining | PubMed |
| Case Report: An NTRK1 fusion-positive embryonal rhabdomyosarcoma: clinical presentations, pathological characteristics and genotypic analyses. | Front Oncol | 2023 | 37188172 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/10499/papers?page=11